UNC Lineberger Comprehensive Cancer Center

Running trials

• Not yet recruiting

  Tirzepatide in Women With Obesity and Endometrial Intra-epithelial Neoplasia or Grade 1 Endometrial Cancer

  NCT07078838· Phase 2· Source

• Not yet recruiting

  BLinatumomab and iNKT in Relapsed B-Cell ALL

  NCT07869368· Phase 1· Source

• Not yet recruiting

  Revumenib, Azacitidine, and VENetoclax in Newly Diagnosed KMT2A-Rearranged AML

  NCT07605949· Phase 2· Source

• Not yet recruiting

  A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple Myeloma

  NCT07728188· Phase 3· Source

• Not yet recruiting

  Characterizing Tumor Hypoxia With BOLD-MRI to Predict Y-90 Treatment Response

  NCT07916376· Source

• Not yet recruiting

  The PharmFIT Study

  NCT06656936· Source

• Recruiting

  A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment

  NCT07293247· Phase 2· Source

• Recruiting

  Bexmarilimab + Azacitidine Versus Placebo + Azacitidine in Participants With Treatment-naïve Higher-risk Myelodysplastic Syndromes

  NCT07672769· Phase 2· Source

• Recruiting

  Assessing Survival Outcomes With Checkpoint Inhibition ExteNded vs Discontinued in Endometrial Cancer

  NCT07867002· Phase 3· Source

• Not yet recruiting

  SURGIMEDIA: Utilization of Multimedia for Enhanced Surgical Consent

  NCT07494994· Source

• Not yet recruiting

  Study on Treatment Outcome Patterns for Patients With CLL After Discontinuation of BTK Inhibitors

  NCT07526597· Phase 2· Source

• Recruiting

  Pharmacologic Therapies to Mitigate Radiation- Associated Heart Disease

  NCT07685938· Phase 2· Source

• Recruiting

  NeoAdjuvant, Spare-Adjuvant (NASA) in Stage IIIB-IV (M1a) Melanoma

  NCT07740941· Phase 2· Source

• Recruiting

  Adding Pirtobrutinib to the Usual Treatment for People With Newly Diagnosed Richter Transformation, The PIRAMID Trial

  NCT07220187· Phase 3· Source

• Recruiting

  Itraconazole in Combination With Ablation for the Prevention of Esophageal Cancer in Patients With High-risk Barrett's Esophagus

  NCT06732388· Phase 2· Source

• Recruiting

  Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia

  NCT07061951· Phase 2· Source

• Recruiting

  A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)

  NCT07513376· Phase 3· Source

• Recruiting

  Strength Training Exercise in Pediatric Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (STEP-ALL)

  NCT07634653· Source

• Recruiting

  Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL

  NCT07321652· Phase 3· Source

• Recruiting

  Tirzepatide in Obesity-Driven Endometrial Cancer

  NCT07065552· Early phase 1· Source

• Recruiting

  Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer

  NCT07195734· Phase 2· Source

• Recruiting

  PREDICT-RD: ctDNA Surveillance in TNBC With Residual Disease

  NCT07069595· Phase 2· Source

• Recruiting

  Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies

  NCT07340541· Phase 2· Source

• Recruiting

  Hyaluronic Acid-based Gel Spacers in Gynecologic Malignancies

  NCT07292818· Phase 1· Source

• Recruiting

  Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer

  NCT07198074· Phase 3· Source

• Recruiting

  Digoxin Medulloblastoma Study

  NCT06701812· Phase 2· Source

• Recruiting

  Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S04)

  NCT07281430· Source

• Recruiting

  Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer

  NCT07061977· Phase 3· Source

• Recruiting

  Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity

  NCT07001748· Phase 2/3· Source

• Recruiting

  Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study

  NCT07097142· Phase 3· Source

• Recruiting

  Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer

  NCT06958328· Phase 3· Source

• Recruiting

  Memantine and Exercise to Improve Cognitive Function and Modulate Biological Pathways of Cognitive Decline During Chemotherapy in Breast Cancer

  NCT06727773· Phase 2· Source

• Recruiting

  A Decisional Intervention for Older Adults With Acute Myeloid Leukemia and Their Caregivers

  NCT06697600· Source

• Recruiting

  PROGRESS: Precision Oncology Using Genomic Reflexive Evaluations for Study Selection and Survival

  NCT06896162· Source

• Recruiting

  Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy

  NCT06724237· Phase 3· Source

• Recruiting

  The Vanguard Study: Testing a New Way to Screen for Cancer

  NCT06995898· Source

• Recruiting

  Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

  NCT06317662· Phase 2· Source

• Recruiting

  Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial

  NCT06770582· Phase 2· Source

• Recruiting

  A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

  NCT06124157· Phase 2· Source

• Recruiting

  Designing Visual Tools to Enhance Cancer Surgeon Decision-making

  NCT06965192· Source

• Recruiting

  A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)

  NCT06401330· Phase 3· Source

• Recruiting

  Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment

  NCT06589804· Phase 3· Source

• Recruiting

  Testing a Standardized Approach to Surgery and Chemotherapy for Type I Pleuropulmonary Blastoma or the Addition of an Anti-cancer Drug, Topotecan, to the Usual Treatment for Types II and III Pleuropulmonary Blastoma

  NCT06647953· Phase 3· Source

• Recruiting

  DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM)

  NCT06805305· Phase 2· Source

• Recruiting

  Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer

  NCT06661720· Phase 3· Source

• Recruiting

  Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer

  NCT06580314· Phase 3· Source

• Recruiting

  Triptorelin for the Prevention of Ovarian Damage in Adolescents and Young Adults With Cancer

  NCT06513962· Phase 3· Source

• Recruiting

  Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial

  NCT06632977· Phase 2· Source

• Recruiting

  Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel

  NCT06483555· Phase 1/2· Source

• Recruiting

  Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer

  NCT06475989· Phase 3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Childhood cancers25 recruiting
• Acute lymphoblastic leukaemia11 recruiting
• Acute myeloid leukemia9 recruiting
• Chronic lymphocytic leukaemia9 recruiting
• Pancreatic cancer9 recruiting
• Head and neck cancer8 recruiting
• Lung cancer8 recruiting
• Bladder cancer7 recruiting
• Multiple myeloma7 recruiting
• Myelodysplastic syndromes7 recruiting
• Ovarian cancer7 recruiting
• Endometrial cancer6 recruiting
• Follicular lymphoma5 recruiting
• Gastric and esophageal cancer5 recruiting
• Kidney cancer5 recruiting
• Triple-negative breast cancer5 recruiting
• Colorectal cancer4 recruiting
• Diffuse large B-cell lymphoma4 recruiting
• Mantle cell lymphoma4 recruiting
• Metastatic breast cancer4 recruiting
• Myeloproliferative neoplasms4 recruiting
• Prostate cancer4 recruiting
• Sarcoma4 recruiting
• Amyloidosis3 recruiting
• Cervical cancer3 recruiting
• Chronic myeloid leukaemia3 recruiting
• Hodgkin lymphoma3 recruiting
• Neuroblastoma3 recruiting
• Obesity3 recruiting
• Glioblastoma2 recruiting
• Liver and biliary tract cancer2 recruiting
• Melanoma2 recruiting
• Neuroendocrine tumours2 recruiting
• Thyroid cancer1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Withdrawn

  Dara-RVd Induction for Newly Diagnosed Multiple Myeloma With Autologous Stem Cell Transplantation

  NCT06348147· Phase 2· Source

• Terminated

  Digital Art Therapy for Young Cancer Survivors

  NCT06789666· Source

• Withdrawn

  Immune Reconstitution Monitoring and Pneumococcal Vaccination in Patients Treated With CAR-T Cells

  NCT07071909· Phase 1/2· Source

• Terminated

  Ropidoxuridine as a Radiosensitizer in Newly Diagnosed IDH-Wildtype Glioblastoma With Unmethylated MGMT Promoter

  NCT06359379· Phase 2· Source

• Completed

  Little Cigar and Cigarillo Warnings for Youth

  NCT06413797· Source

• Terminated

  Abequolixron (RGX-104) and Durvalumab in Lung Cancer

  NCT05911308· Phase 1· Source

• Completed

  Mobile Weight Loss Intervention for Adolescent and Young Adult Cancer Survivors

  NCT06171945· Source

• Completed

  Measuring Changes in Body Composition and Physical Function in Patients With Childhood Cancers

  NCT05823740· Source

• Terminated

  Polatuzumab Vedotin With R-GDP in Relapsed/Refractory Diffuse Large B-cell Lymphoma

  NCT05498220· Phase 2· Source

• Completed

  Physical Function During ARSI Treatment

  NCT05612880· Source

• Terminated

  Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects With MDS or AML

  NCT05275439· Phase 1· Source

• Withdrawn

  Neoadjuvant Therapy for Localized Rectal Adenocarcinoma

  NCT04418895· Phase 2· Source

• Completed

  Pivotal, Randomized, Open-label Study of Optune® (Tumor Treating Fields) Concomitant With RT & TMZ for the Treatment of Newly Diagnosed GBM

  NCT04471844· Source

• Completed

  Binimetinib and Palbociclib or TAS-102 in Treating Patients With KRAS and NRAS Mutant Metastatic or Unresectable Colorectal Cancer

  NCT03981614· Phase 2· Source

• Completed

  Durvalumab With Radiotherapy for Adjuvant Treatment of Intermediate Risk SCCHN

  NCT03529422· Phase 2· Source

• Completed

  High Intensity Interval Training in Endometrial Cancer

  NCT04025229· Source

• Completed

  Evaluating Sexual Function in Women Undergoing a Radical Cystectomy for Bladder Cancer

  NCT05399004· Source

• Completed

  GRADE-SRM: Genomic Risk Assessment and Decisional Evaluation for Small Renal Masses

  NCT03819569· Source

• Completed

  BV-CHEP Chemotherapy for Adult T-cell Leukemia or Lymphoma

  NCT03264131· Phase 2· Source

• Completed

  Testing the Effects of Palbociclib and Fulvestrant or Letrozole for Patients 70 Years of Age of Older With Metastatic Breast Cancer

  NCT03633331· Phase 2· Source

• Completed

  Study of Crenolanib vs Midostaurin Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed FLT3 Mutated AML

  NCT03258931· Phase 3· Source

• Completed

  Navtemadlin and Radiation Therapy in Treating Patients With Soft Tissue Sarcoma

  NCT03217266· Phase 1· Source

• Completed

  Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin

  NCT03258554· Phase 2/3· Source

• Completed

  Palbociclib and Cetuximab in Metastatic Colorectal Cancer

  NCT03446157· Phase 2· Source

• Completed

  PhII Trial Panitumumab, Nivolumab, Ipilimumab in Kras/Nras/BRAF Wild-type MSS Refractory mCRC

  NCT03442569· Phase 2· Source

• Completed

  Atezolizumab With or Without Cobimetinib in Treating Patients With Metastatic Bile Duct Cancer That Cannot Be Removed by Surgery or Gallbladder Cancer

  NCT03201458· Phase 2· Source

• Recruiting

  A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy

  NCT03394365· Phase 3· Source

• Completed

  Biospecimen Analysis in Determining Effects of Chemotherapy on Fertility in Osteosarcoma Survivors

  NCT03206450· Source

• Completed

  Testing Treatment With Ipilimumab and Nivolumab Compared to Treatment With Ipilimumab Alone in Advanced Melanoma

  NCT03033576· Phase 2· Source

• Terminated

  A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer

  NCT03288545· Phase 1/2· Source

• Terminated

  Afatinib in Advanced Refractory Urothelial Cancer

  NCT02122172· Phase 2· Source

• Completed

  Hypofractionated Radiation Therapy or Conventional Radiation Therapy After Surgery in Treating Patients With Prostate Cancer

  NCT03274687· Phase 3· Source

• Completed

  Apixaban in Preventing Secondary Cancer Related Venous Thrombosis in Cancer Patients Who Have Completed Anticoagulation Therapy

  NCT03080883· Phase 3· Source

• Completed

  Testing the Safety and Efficacy of the Combination of the Antibody Pembrolizumab and Entinostat in Patients With Myelodysplastic Syndrome Who Are Not Responding to Hypomethylating Agents

  NCT02936752· Phase 1· Source

• Completed

  A Study of Rucaparib Versus Physician's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency

  NCT02975934· Phase 3· Source

• Completed

  Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement

  NCT02828358· Phase 2· Source

• Completed

  Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases

  NCT02595905· Phase 2· Source

• Completed

  Osimertinib and Navitoclax in Treating Patients With EGFR-Positive Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer

  NCT02520778· Phase 1· Source

• Completed

  High Dose Cytarabine Followed by Pembrolizumab in Relapsed/Refractory AML

  NCT02768792· Phase 2· Source

• Completed

  Pivotal, Open-label, Randomized Study of Radiosurgery With or Without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases From Non-small Cell Lung Cancer (NSCLC).

  NCT02831959· Phase 3· Source

• Completed

  Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma

  NCT02807636· Phase 3· Source

• Completed

  Pembrolizumab + Radiation for Locally Adv SCC of the Head and Neck (SCCHN) Not Eligible Cisplatin

  NCT02609503· Phase 2· Source

• Completed

  Denosumab in Treating Patients With Recurrent or Refractory Osteosarcoma

  NCT02470091· Phase 2· Source

• Terminated

  Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

  NCT02408861· Phase 1· Source

• Completed

  Testing Whether Treating Breast Cancer Metastases With Surgery or High-Dose Radiation Improves Survival

  NCT02364557· Phase 2/3· Source

• Completed

  Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery

  NCT02180867· Phase 2/3· Source

• Completed

  Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer

  NCT02101788· Phase 2/3· Source

• Completed

  Metformin With the Levonorgestrel-Releasing Intrauterine Device for the Treatment of Complex Atypical Hyperplasia (CAH) and Endometrial Cancer (EC) in Non-surgical Patients

  NCT02035787· Phase 2· Source

• Completed

  Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer

  NCT02003209· Phase 3· Source

• Completed

  Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma

  NCT01979536· Phase 2· Source

Trial sites

• Lineberger Comprehensive Cancer Center21 trials
• Lineberger Comprehensive Cancer Center at the University of North Carolina at Chapel Hill1 trial
• Lineberger Comprehensive Cancer Center at University of North Carolina4 trials
• Lineberger Comprehensive Cancer Center at University of North Carolina, Chapel Hill26 trials
• Lineberger Comprehensive Cancer Center, University of North Carolina2 trials
• The UNC Lineberger Comprehensive Cancer Center1 trial
• UNC Cancer Center1 trial
• UNC Lineberger Comprehensive Cancer Center283 trials
• UNC Lineberger Comprehensive Cancer Center (Site 3250)1 trial
• UNC Lineberger Comprehensive Cancer Center / University of North Carolina2 trials
• University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center6 trials
• University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center (Adults and Pediatrics)1 trial
• University of North Carolina at Chapel Hill, UNC Lineberger Comprehensive Cancer Center1 trial
• University of North Carolina Brain Tumor Program - UNC Lineberger Comprehensive Cancer Center1 trial
• University of North Carolina - Chapel Hill Comprehensive Cancer Center1 trial
• University of North Carolina Lineberger Cancer Center1 trial
• University of North Carolina, Lineberger Cancer Ctr1 trial
• University of North Carolina Lineberger Comprehensive Cancer Center6 trials
• University of North Carolina Lineberger Comprehensive Cancer Center /ID# 2814541 trial
• University of North Carolina (UNC) - Lineberger Comprehensive Cancer Center1 trial
• UNC Lineberger Comprehensive Cancer Center1 trial

Conditions

Diseases this institution publishes on or runs trials for.

• Triple-negative breast cancer31 works · 11 trials
• Pancreatic cancer28 works · 15 trials
• Bladder cancer27 works · 21 trials
• Metastatic breast cancer23 works · 17 trials
• Endometrial cancer16 works · 16 trials
• Myelodysplastic syndromes8 works · 15 trials